Pavel Reiterer
22 works · 648 citations · h-index 9
Top works
- Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
- Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
- EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis
- Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer
- O-099 XYOTAX™ vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): The STELLAR 2 phase III study
- Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study
- Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis
- Vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter Czech study.
- Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial
- Léčba neoperabilního nemalobuněčného bronchogenního karcinomukombinací cisplatiny a vinorelbinu - průběžné hodnocení
- Druhá linie léčby malobuněčného bronchogenního karcinomumonoterapii topotecanem-doplněný soubor nemocných 2005-2008čtyř pracovišť. Aktuální stav v diagnostice relapsumaloobuněčné rakoviny plic, množství léčby ve druhé a dalšíchliniích.
- Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin(CBDCA) as first line treatment in advenced non-small lungcancer (NSCLC) patients: results of a prospective study innonrandomized and unselected population of 396 patient
- Kombinovaná léčba nemalobuněčného neoperabilního karcinomuvinorelbinem a cisplatinou
- EMPIRE Registry, Czech Part: Impact of Demographics, PulmonaryFunction and HRCT on Survival and Clinical Course inIdiopathic Pulmonary Fibrosis
- Peronální vinorelbin den 1. a den 8. v kombinaci skarboplatinou v léčbě nemocných s pokročilým nemalobuněčnýmkarcinomem plic (NSCLC): výsledky nerandomizované studie uneselektované populace 396 nemocných
- Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients
- Vinorelbine and Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer: Results of a Multicentric Czech Study
- Essai de phase 3 Vinorelbine (NVB)-carboplatine (CBDCA) vs Vinorelbine-Gemcitabine (GEM) pour les patients (pts) ayant un CNPC : GLOB 2
- 58 GLOB 2: a randomised phase III study comparing doublets including navelbineâ (NVB) with either gemcitabine (GEM) or carboplatin (C) in inoperable non-small-cell lung cancer (NSCLC) patients